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Abstract 
 
Survival following lung transplantation is lower than survival following all other solid 
organ transplants. Chronic rejection, graft failure, and opportunistic infections all contribute to 
these poor outcomes. One such opportunistic infection is cytomegalovirus (CMV). CMV is one of 
the most common infections after lung transplant and can cause direct effects (viremia and 
disease), and indirect effects including increased risk of acute cellular rejection, and death. Donor 
CMV serology positive, recipient negative (D+/R-) patients have the highest risk for developing 
CMV, for which they receive extended valganciclovir prophylaxis. Longer prophylaxis durations, 
however, may lead to an increased risk of infection due to resistant CMV, and no standardized 
guidelines exist for prophylaxis duration. To investigate the effect of duration length on survival, 
a cost-effectiveness analysis of mismatch and non-mismatch patients was performed, where non-
mismatch patients received 6 months of prophylaxis and mismatch patients received either 1 or 2 
years. A Markov-state transition model was used, with month-long cycles over a five-year time 
horizon, a 3% discount rate, and took a healthcare system perspective. Health states of no CMV, 
sensitive and resistant CMV viremia, sensitive and resistant CMV disease, and death are modeled, 
with possible episodes of acute cellular rejection in each state. Outcomes included life-years 
gained and quality-adjusted life-years (QALYs). The model showed that increasing prophylaxis 
duration resulted in gains in both life-years and QALYs. Incremental cost-effectiveness ratios were 
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v 
$110,510 per life-year gained and $150,280 per QALY. Continued prophylaxis for 5 years after 
transplant increases the ICER to $153,862 per life-year gained, and $203,756 per QALY. These 
results show that extended valganciclovir prophylaxis for mismatch patients is associated with 
gains of life-years and QALYs and is economically reasonable. As only a limited number of lungs 
are available, and the demand outweighs the supply, extended prophylaxis would result in these 
organs being used to their greatest benefit, and could decrease the need for re-transplants, showing 
a clear public health impact.  
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1.0 Introduction 
1.1 Lung Transplantation and Cytomegalovirus 
      Lung transplantations have been regularly performed since the 1980s, though first 
performed in 1963 by Dr. Thomas Hardy [1]. It is treatment option for a variety of diseases 
resulting in end-stage lung disease when other treatments are either not an option or 
unsuccessful [2]. More recently, clinical, surgical, and pharmacological advances have 
improved outcomes for patients undergoing lung transplantation. In 2000, patients had a 50% 2-
year survival post-transplant; by 2014, they had a 50% 6-year survival after transplantation 
[3]. More patients receive lung transplants each year, and more people are on the waiting list 
to receive a transplant. In 2018, 2,565 lung transplants were performed in the United States, and 
the number of people on the waiting list grew by 233 [4]. 
Some improvements in outcomes can be attributed to the US implementation of the lung 
allocation score (LAS) in 2003, which provided a new system for donor lung allocation [2]. Under 
the LAS, allocation is done on the basis of medical need and benefit, rather than on time on the 
waiting list [2, 3]. The LAS considers a number of factors, including pre- and post-transplant 
survival; age, geography, blood type compatibility, and waiting time when making allocation 
decisions [4].  
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However, multiple challenges surrounding lung transplantation remain. There are still too 
few donors relative to the length of the waiting list. As a result, some wait-listed patients die before 
receiving a transplant – in 2018, 365 people either died on the waitlist, or became too sick to be 
transplanted [1, 4, 5]. Because of immunosuppression use following transplantation, both graft 
failure and chronic rejection contribute to post-transplant mortality, as do opportunistic infections 
[1, 3]. 
One such opportunistic infection is cytomegalovirus (CMV). CMV is the most common 
opportunistic infection following lung transplantation [6, 7]. CMV incidence following lung 
transplantation is higher than in other solid organ transplants; without prophylaxis, the incidence 
is estimated to range from 54 – 92% [8]. The most important risk factor associated with CMV 
acquisition following transplant is donor +, recipient – (D+/R-) serostatus [8]. CMV can be present 
as infection, or the more serious disease. CMV infection is generally defined by a positive culture, 
associated with active replication and shedding of the virus, while CMV disease is defined by 
CMV presence within cell preparations or tissue [9].  
To minimize CMV risk following lung transplantation, prophylaxis with antivirals like 
ganciclovir or valganciclovir is recommended [7, 9]. Generally, D+/R- patients receive between 3 
and 6 months of prophylaxis after transplantation, though there is currently no consensus around 
optimal prophylaxis duration [7, 10]. Though prophylaxis can reduce CMV incidence, it also 
increases the risk of resistant CMV strains. An estimated 3 – 16% of cases are resistant, which is 
associated with decreased patient survival [11]. Resistant CMV is treated with IV Foscarnet, which 
is effective but associated with nephrotoxicity [9, 11]. Thus, any extended prophylaxis duration 
must be weighed against the increased risk of resistant CMV strains. 
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1.2 Introduction to Cost-Effectiveness Analysis 
One way to investigate optimal prophylaxis duration following lung transplantation is to 
perform a cost-effectiveness analysis (CEA). CEAs compare the costs and effectiveness of one 
strategy, usually a treatment or some other intervention, to one or more alternatives [12, 13]. The 
comparison is the difference in costs between strategies divided by the difference in strategy 
effectiveness to calculate the incremental cost-effectiveness ratio (ICER). Effectiveness can be 
measured in different ways – some examples include deaths averted, number of cases of a disease 
prevented, or quality-adjusted life-years (QALYs) [13].  
QALYs are the most commonly used measurement of effectiveness, calculated by 
multiplying a health state utility values by the length of time a person spends in that state [12-14]. 
These utilities are elicited either directly, on a person-by-person basis, indirectly, through a 
preference-based questionnaire, or can be estimated from previously-published literature. 
There are three common ways of directly eliciting a utility value – the standard gamble 
(SG), time trade-off (TTO), and visual analog scale (VAS). The SG poses the question of 
remaining in a certain health state, or “gambling,” with a probability of returning to full health and 
a corresponding probability of death [14]. This probability is then varied until the indifference 
point is reached – when there is no longer a preference between the current health state and the 
probability of death [14]. This probability then becomes a utility value – if a person were 
indifferent at a 60% chance of death, the utility is 0.60. The TTO offers the choice of continuing 
to live in a particular health state for the remaining life time, or living in perfect health for a shorter 
period of time [14]. Just as with the SG, this amount of time living in perfect health is varied until 
the indifference point is reached [13]. The utility score is then ascertained by dividing the amount 
of time at the point of indifference by the life expectancy [14]. If an indifference point of 7 years 
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was found, and the choice was between that and 10 years in current health, the utility score would 
be 0.70. The VAS is the simplest of the 3 direct elicitation methods. A scale is drawn with a single 
line, ranging from 0 – 100, and users are asked to mark on the scale their measurement for the 
health state being questioned [14]. If 73 were marked, for example, the utility score would then be 
0.73. 
 Often, however, it is not feasible to perform a direct elicitation of a utility score. More 
commonly, indirect elicitation is performed using a generalized questionnaire. The two most 
frequently used are the EQ-5D and the SF-6D [14]. The EQ-5D contains 5 domains – mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression – and within each domain, 
participants are asked to select whether they have no problems, slight problems, moderate 
problems, severe problems or extreme problems [15]. Using a validated calculation, these scores 
are then transformed into a utility score [14]. The SF-6D is a condensed version of the SF-36, a 
questionnaire from RAND that contains 8 domains and 2 summary scores [16, 17]. The domains 
included are physical functioning, role limitations due to physical health, role limitations due to 
emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general 
health; the summary scores are the physical component score and the mental component score 
[16]. The SF-6D uses a subset of the questions from the SF-36, and comprises 18,000 health states 
[17]. Using a validated model, utility scores can then be obtained from the SF-36 for use in cost-
effectiveness analyses [17]. 
There are times that neither direct or indirect elicitation of utility values are feasible, 
because the analysis being done uses retrospective data, rather than prospective. In these cases, the 
utility values will not come from any type of elicitation, but rather, will come from utility estimates 
used in previously published research studies or analyses. 
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1.3 Public Health Significance of CMV Following Lung Transplantation 
The public health significance of lung transplant and maximizing mortality following 
transplantation is clear. The shortage of donor lungs is a problem on a population level – a shortage 
of donors means that there is an increased risk of death while on the transplant waiting list. Overall, 
< 2% of all eligible lungs are actually used in transplant in the US, often due to concerns about 
donor history, chest trauma, or other ICU complications [1]. This results in 10 – 13% of those on 
the waiting list dying before they can be transplanted [1]. Furthermore, the 5-year mortality 
following transplantation is around 55%, lower than many other solid organ transplants [1]. With 
limited donors and limited survival 5 years post-transplant, it is imperative that informed decisions 
about CMV treatment be investigated in order to maximize the efficacy of the donor organs 
transplanted, and to improve the post-transplant survival rates. 
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2.0  Literature Review 
To better understand the importance of proper CMV prophylaxis following lung 
transplantation, it is important to first understand the complicated relationship between lung 
transplantation, CMV, and graft failure. As stated earlier, CMV incidence is higher in lung 
transplant recipients, and those at highest risk are D+/R- [8]. CMV infection can develop after 
transplantation through transmission from a donor-positive organ, a donor-positive blood 
transfusion, or a reactivation of a latent infection in a positive transplant recipient [9]. CMV is 
associated with acute and chronic allograft rejection, but it is not clear if the relationship is causal 
[8, 11]. It is suspected that CMV infection of the vascular endothelium and smooth muscle cells 
likely plays a role in acute and chronic rejection; CMV also induces anti-endothelial cell 
antibodies, which may lead to the development of chronic rejection in the long term [11]. In lung 
transplant recipients, pneumonia is the most common presentation of CMV, though hepatitis, 
gastroenteritis, and colitis are also seen [9]. Furthermore, in lung transplant recipients, CMV is 
associated with bronchiolitis obliterans syndrome (BOS), which is progressive and the major factor 
affecting post-transplant mortality [7, 9, 11]. Once BOS is present, median survival is around 3 
years [7]. Because BOS is progressive even with heightened treatment, prevention is key to 
increasing survival after lung transplant [11]. 
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2.1 Prevention of CMV 
There are 2 major strategies for preventing CMV infection – pre-emptive therapy, and 
prophylaxis. 
Pre-emptive therapy relies on continual testing of patients following transplantation to 
identify infection before the emergence of disease [9]. If this strategy is used, its recommended 
that patients be monitored daily immediately following transplant, then weekly for 6 weeks, then 
every 2 weeks until 12 weeks post-op, and monthly following week 12 [8]. Pre-emptive therapy 
may be selected because only those who are actually sick are treated, and it can decrease costs and 
decrease the risks of resistant strains emerging [9]. However, there is still a cost associated with 
the increased monitoring, and it’s possible that cases of CMV disease can still be present even 
though the infection escaped detection [11].  
 Thus, especially for D+/R- transplant recipients, prophylaxis is much more common. Most 
patients receive between 3 and 6 months of prophylaxis, though some receive less and some 
receive more [7]. Initially, the prophylaxis regimen was IV or oral ganciclovir for 1 – 3 months 
following transplant, now, the most commonly used regiment is IV ganciclovir followed by oral 
valganciclovir (valganciclovir), or just oral valganciclovir, for 3 – 6 months [7]. During this time, 
patients should still be monitored – every 2 weeks for the first 6 monthly, and then monthly after 
that [8]. The use of CMV hyperimmune globulin (CMV-IVIG) has improved outcomes when used 
in conjunction with valganciclovir prophylaxis, though not when used alone [11]. A major 
limitation of prophylaxis, however, especially in the short-term, is that almost half of at-risk 
patients develop CMV after prophylaxis is discontinued [7]. 
 8 
2.2 Treatment of CMV 
CMV infection or disease can develop during prophylaxis, known as breakthrough CMV, 
or after prophylaxis has been discontinued. CMV infection and disease are generally treated with 
IV ganciclovir twice a day for 2 – 4 weeks, or until the viral load is reduced to levels below 
detection upon testing [8, 11]. Often, CMV IVIG will also be added as treatment, especially for 
treatment of pneumonia or colitis [11]. Recurrence, however, is common, and treatment should be 
repeated when that occurs [9]. 
Resistant CMV should be suspected when patients do not respond to IV ganciclovir 
treatment, or when there are persistent episodes of recurring infection either during prophylaxis or 
following its discontinuation [8, 11]. Foscarnet is generally used as treatment for resistant CMV, 
though a combination of Foscarnet and IV ganciclovir is sometimes used [8, 9, 11]. Typically, 
patients receive 21 days of Foscarnet, and then a lower maintenance dose of the drug for an 
additional 30 days [8]. Foscarnet is effective, but is associated with an increased risk of 
nephrotoxicity [9]. 
2.3 Lack of Best Practice Consensus 
To minimize the risk of CMV infection and disease among those at high risk (D+/R-), 
current guidelines from the American Society of Transplant Infectious Diseases recommend 6 
months of prophylaxis [7]. Various reports have indicated that extending prophylaxis beyond 6 
months may be reasonable. One placebo-controlled RCT found that lifetime CMV risk (4 years 
after transplantation) was decreased when 12 months of prophylaxis were used [7]. A few other 
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single transplant centers have reported 12 months or longer of prophylaxis, but concerns regarding 
increased costs, risk of resistance, and toxicity remain [7]. Currently, there is no consensus 
regarding the optimal duration of CMV prophylaxis following lung transplantation [10]. This lack 
of consensus surrounding best practices lends itself to a CEA focused on the ideal length of 
prophylaxis for CMV. 
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3.0  Hypothesis or Expected Outcomes 
Generally, the results from a CEA can take a few forms. One strategy may be more 
effective and less costly. When this occurs, the recommendation is to choose that strategy, as there 
is no downside – they are considered to be economically dominant [12]. Conversely, a strategy 
may be less effective and more costly. In this situation, that strategy would not be recommended, 
as it is worse in terms of costs and benefits – this is considered to be economically dominated [12]. 
Often, however, a strategy will be more effective but also more costly. When this occurs, the 
strategy is compared against a cost-effectiveness threshold – essentially, the amount of money 
considered to be acceptable to expend to gain one QALY [12]. Historically, that threshold was set 
at $50,000/QALY in the US, which originated from the 1970s and is related to the cost of dialysis 
for patients with end-stage renal failure at that time [12]. Current recommendations suggest the 
use of not one single threshold, but rather multiple thresholds of $50,000, $100,000, and 
$200,000/QALY [18]. Decision makers could then assess results based on those thresholds and 
decide which threshold is most appropriate for them specifically, based on the available resources 
and possible alternate uses of those resources [18]. 
 When looking to the question of prophylaxis duration following lung transplantation, it is 
likely that our result will fall into this last category, increased effectiveness at some increased cost. 
Increasing the length of time a patient is receiving prophylaxis will certainly come with an 
increased cost, as will the cost of treating resistant CMV strains that may be more likely to be 
present. While it is possible that increasing the duration of prophylaxis could result in a decrease 
of effectiveness due to the toxicity of treatment for resistant CMV, this is not likely, as studies thus 
far have shown the opposite. In the case of prophylaxis duration following lung transplantation, 
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the most likely outcome is that increased duration will see increased benefits along with increased 
costs, and the decision to implement a longer prophylactic regimen will depend on the cost-
effectiveness threshold chosen. 
 12 
4.0  Design, Methodology, and Data 
4.1 Rationale for Choosing A CEA 
As stated above, performing a cost-effectiveness analysis on prophylaxis duration after 
lung transplantation will allow us to compare different lengths of prophylaxis on both high risk 
(D+/R- “mismatch”) patients and non-mismatch patients. A CEA allows us to take into account 
different costs and benefits for both types of patient cohorts, and for different prophylaxis 
durations. Additionally, sensitivity analyses can be performed, where each of the model parameters 
can be varied to capture the effects of any uncertainties.  
When using a CEA, we can model hypothetical cohorts of simulated patients. A 
hypothetical cohort creates simulated patients, with characteristics, probabilities, and utility values 
that come from previously published literature. This hypothetical cohort is then used to populate 
the model – specifically, in this case, used to create the simulated patients that are given differing 
lengths of prophylaxis. Modeling in this way allows for the use of retrospective data found in 
published literature to compare differing prophylaxis durations on simulated, rather than real, 
patients. 
The CEA will model the trajectories of these simulated patients, following them through 
cycles of infection, disease, and recovery, and capturing the costs and health benefits that they 
receive, or lose, as they pass through these health states. Specifically, the model chosen is a Markov 
state transition model. Markov models are most useful when examining sequential decisions made 
over time, because they operate in cycles. At the end of each cycle, the simulated patient may 
transitioned to a new health state, based on a probability of that transition occurring found in the 
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literature; they also accumulate QALYs according to the health state that they are in and the 
amount of time spent in it [19, 20]. 
4.2 Details of the Model and Patient Trajectories 
This specific Markov model was built using TreeAge Pro 2017 (TreeAge Software, 
Williamstown MA). Both mismatch and non-mismatch patients are included in the model, just as 
they would be in actual clinical practice. The model uses month-long cycles, meaning that 
simulated patients can move between health states each month, and has a 5-year time horizon. The 
model also utilizes a healthcare system perspective, in which costs considered are direct medical 
costs incurred to the healthcare system, rather than societal, which also considers costs like missed 
wages due to illness. Future costs and effectiveness are discounted at 3% per year. 
Health states of no CMV, viremia and disease due to sensitive and resistant CMV, and 
death are included in the model. Each state also accounts for episodes of acute cellular rejection 
(ACR). These health states are the states that simulated patients move between while moving 
throughout the model – the possible health states that they can experience. When comparing the 
durations of prophylaxis, different strategies were compared using the ICER (difference in costs 
between strategies divided by the difference in effectiveness). The effectiveness was measured 
both in QALYs and in life-years gained. 
All patients begin in the no CMV health state and, based on clinical estimates, we model 
20% as mismatch patients. From the no CMV state, simulated patients move throughout the model 
as shown in Figure 1. Patients can either continue to remain CMV-free or can progress to CMV 
viremia. Patients with viremia can progress to viremia due to resistant virus, disease due to 
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sensitive virus, remain the same, or improve and return to the no CMV state. Likewise, patients 
with sensitive disease can progress to disease due to resistant virus, remain the same, or improve 
and return to the no CMV state. As patients continue to move through the model, we assume that 
a worsening patient either movies from viremia to disease, or from a sensitive to resistant virus. 
Similarly, patients who improve are assumed to return to the no CMV state. From this point, 
patients can again remain CMV-free, or can progress once more to a CMV state, simulating the 
recurrence of CMV that is seen clinically. Patients can also remain the same – spend multiple 
cycles in the same health state – which simulates the needs for additional rounds of treatment. 
Each of these states also includes the risk of developing acute cellular rejection concurrently. Death 
can occur from any state in the model. 
 
 
Figure 1. Markov State Transition Diagram of Possible States and Transitions in the Model  
 15 
 Non-mismatch patients receive 6 months of prophylaxis in the model, which is the standard 
length of prophylaxis for these patients in clinical practice. Mismatch patients receive either 1 year 
of prophylaxis, as is standard clinically, or they receive an extended prophylaxis duration of 2 
years. Prophylaxis consists of 900 mg of valganciclovir and CMV PCR testing. Episodes of 
sensitive CMV viremia are treated with IV ganciclovir for 3 weeks, followed by valganciclovir 
prophylaxis for 3 months, and weekly CMV PCR tests for 3 months. Resistant CMV viremia is 
first treated as an inpatient, and then on an outpatient basis with 3 months of Foscarnet, a weekly 
CMV PCR, laboratory surveillance 3 times a week, intravenous (IV) replenishment of fluids, 
potassium, and magnesium. Of the patients receiving Foscarnet, 10% are assumed to develop renal 
failure which requires hemodialysis. Acute cellular rejection (ACR) is assumed to be treated in the 
hospital as well. 
4.3 Data Sources 
4.3.1 Probabilities 
The probabilities used to populate the model for CMV-related risks and rejection 
occurrence were obtained from national estimates for mismatch and non-mismatch patients, and 
clinical assumptions where no national estimates exist. The use of national estimates, rather than 
clinic-specific probabilities, allow for broad generalization and application of the model, and 
account for regional differences that may exist. From published literature, probabilities for 
developing CMV viremia and disease, probability of infection due to valganciclovir-sensitive or 
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resistant CMV, mortality risk from CMV, ACR risk, and other probabilities for moving between 
states in the model were obtained, as shown in Table 1. 
 
Table 1. Model Probability Parameters 
 
While on prophylaxis, patients have a 10% chance of developing CMV (considered 
“breakthrough” CMV); once off prophylaxis, mismatch patients have a 50% chance of developing 
CMV, and non-mismatch patients have a 30% chance of developing CMV. Resistant strains of 
CMV are estimated to occur in 5% of non-mismatch patients, and in 15% of mismatch patients 
Probabilities Base Case Range Reference 
 Nonmismatch Mismatch Nonmismatch Mismatch  
 Develop CMV on 
prophylaxis 
10 10 0-30 0-30 [21] 
 Develop CMV off 
prophylaxis 
30 50 25-86 25-86 [9, 11] 
 Progress to CMV 
Disease 
20 20 15-30 15-30 Assumed 
 Progress to resistant 
viremia 
5 15 3-9 9-27 [11, 22] 
 Progress to resistant 
disease 
5 15 3-9 9-27 [11, 22] 
 Episode of ACR 21 33 18-25 27-39 [21]; 
Assumed 
 Death without CMV 10 8 8-12 6-10 [23] 
 Death from viremia 5 5 0-10 0-10 [11] 
 Death from disease 20 20 10-30 10-30 [8] 
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(cite Limaye). Episodes of ACR are estimated to occur at different rates not based on mismatch 
status, but rather on CMV status – ACR is estimated to occur among 21% of patients in the no 
CMV state, and among 32% of patients in any of the CMV states, due to the association between 
CMV and ACR [21]. For use in the model, these yearly probabilities are converted into monthly 
probabilities. 
4.3.2 Costs 
As mentioned, the model takes a healthcare system perspective, so costs included in the 
model include the prophylaxis regimen for mismatch and non-mismatch patients, CMV PCR 
testing, treatment of sensitive and resistant CMV viremia and disease, and treatment of ACR, as 
seen in Table 2. When including the costs of treatment for CMV, the possibility of additional 
rounds of treatment is also considered. When considering treatment of resistant strains, the costs 
considered are inpatient costs, the outpatient treatment costs that follow, and the cost of testing for 
resistance. 
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Table 2. Model Cost and Utility Parameters 
 
 Monthly prophylaxis, while patients are receiving it, costs $2,498, which includes the cost 
of valganciclovir plus the cost of filgrastim for a portion of the patients. Each cycle of treatment 
of viremia costs $16,413, which includes ganciclovir treatment and the PCR testing to ensure that 
the viremia has been successfully treated. Treating CMV disease costs $26,663, which again 
includes the costs of ganciclovir for treatment, PCR testing, and filgrastim for 6% of patients. 
Treatment of resistant viremia is $53,938, and resistant disease is $60,866 – treatment of resistant 
cases comprise both an inpatient and outpatient cost, where the outpatient cost includes labs for 
Parameters Base Case Range Reference 
Costs    
 Acute Rejection $16,019 $12,815-$19,222 [24] 
 Monthly Prophylaxis $2,498 $1.998-$2,997 [25] 
 CMV Viremia $16,414 $13,131-$19,696 [25, 26] 
 Resistant CMV Viremia $53,938 $43,150-$64,725 [25-27] 
 CMV Disease $26,663 $21,330-$31,996 [25, 26] 
 Resistant CMV Disease $60,866 $48,693-$73,039 [25-27] 
Utilities    
 No CMV  0.70 0.50-0.90 [28] 
 CMV viremia 0.65 0.45-0.85 [29] 
 Resistant CMV viremia 0.65 0.45-0.85 [29] 
 CMV disease 0.50 0.30-0.70 [29] 
 Resistant CMV disease 0.50 0.30-0.70 [29] 
 Episode of ACR 0.50 0.30-0.70 [29] 
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electrolyte levels, fluid, potassium, and magnesium replacement, and hemodialysis for 10% of 
patients. Episodes of ACR, which occur concurrently with costs of CMV, are treated as an inpatient 
cost of $16,019. 
4.3.3 Utilities 
All utility values for health states are estimated from published literature, and can be found 
in Table 2. Patients without CMV have a utility value of 0.70, patients with sensitive or resistant 
viremia have a utility value of 0.65, and patients with sensitive or resistant disease have a utility 
value of 0.50. Episodes of ACR have a utility of 0.50. For ACR, the utility of rejection and CMV 
are both considered, with the combined utility being calculated by multiplication (e.g. utility of an 
episode of ACR combined with sensitive CMV disease = 0.5 * 0.5 = 0.25). 
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5.0  Findings and Results 
When conducting the base-case analysis, the ICER was calculated between strategies of 
differing duration lengths as a ratio of the difference between the costs relative to the difference in 
the effectiveness, measured in both life-years gained and quality-adjusted life-years. In addition to 
the base-case analysis, one-way sensitivity analyses were performed – all parameters were varied 
individually over reasonable ranges. Furthermore, a Monte Carlo probabilistic analysis was 
performed, where all model parameters were varied simultaneously over their distributions as 
listed in Tables 1 and 2. For probability and utility values, the distributions fitted were  
distributions, which have a possible range of 0 – 1. The cost variables were fitted with  
distributions, which have possible values of  0. 
5.1 Base Case Analysis 
For the base case analysis, the model is run with the base case values for probabilities, 
costs, and utility values, for both outcomes of QALYs and life-years gained. In the base case, one 
year of prophylaxis costs $61,130, and increasing the duration to two years costs $63,453 – an 
increase of $2,323 for the additional year of prophylaxis. Effectiveness in terms of life-years 
gained is 3.375 for one year of prophylaxis, and increases to 3.396 for a two year duration. 
Similarly, effectiveness in terms of quality-adjusted life-years is 2.351 and 2.396 for one and two 
years of prophylaxis, respectively. Thus, as duration of prophylaxis increases, both costs and 
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effectiveness also increase. This results in an ICER of $110,510/life-year gained, and 
$150,280/QALY when considering the base-case scenario, as seen in Table 3.  
 
Table 3. Base-case Results 
 
  
As mentioned, an ICER of $50,000/QALY was used historically, but is now considered to 
be outdated. Instead, the ICER can be considered against the previously-suggested thresholds of 
$50,000, $100,000, and $200,000 per QALY. When using these recommendations, the base case 
result of $150,280/QALY falls under the upper threshold of $200,000 per QALY. 
Strategy Cost 
Incremental 
Cost Effectiveness  
Incremental 
Effectiveness ICER 
Life-years gained 
1 year 
prophylaxis 
$61,131 -- 3.375 -- -- 
2 years 
prophylaxis 
$63,453 $2,323 3.396 0.021 110,510 
QALYs gained 
1 year 
prophylaxis 
$61,131 -- 2.350 -- -- 
2 years 
prophylaxis 
$63,453 $2,323 2.366 0.015 150,280 
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5.2 One-Way Sensitivity Analyses 
When conducting one-way sensitivity analysis, each individual parameter in the model is 
varied over a reasonable range, and the ICER is calculated again under these ranges of values. 
One-way sensitivity analyses were performed for each variable, and found that only the probability 
of CMV while on prophylaxis being varied led to one year of prophylaxis being preferred over the 
longer, two year prophylactic regimen. If a $200,000/QALY threshold is selected, one year of 
prophylaxis becomes preferred when the risk of CMV while on prophylaxis increases to 22%, 
from the base-case risk of 10%, as seen in Figure 2. 
 
 
Figure 2. Change in Incremental Cost-effectiveness Ratio (ICER) with Varying Risk of Breakthrough CMV 
While on Prophylaxis 
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In the base-case scenario, the probability of being a mismatch patient is 20%, which mirrors 
lung transplant patients on a national level. Of course, it is possible that a particular region, city, 
or transplant clinic location may have a lower or higher than average percentage of CMV mismatch 
patients. When the probability of mismatch is varied in a one-way sensitivity analysis, as the 
probability increases, so does the average cost of treatment, as seen in Figure 3. However, since 
the probability of mismatch affects both the one-year and two-year prophylaxis arms equally, the 
differences in costs and effectiveness between strategies are proportionate to each other, and thus 
the incremental cost-effectiveness of the 2-year strategy remained unchanged with variation of 
mismatch likelihood. 
 
 
 Figure 3. Change in Average Cost with Varying Probability of Mismatch Status 
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prophylaxis duration is increased to the entirety of the five-year time horizon that the model 
simulates, the ICER increases to just over $200,000/QALY, as seen in Figure 4. 
 
 
Figure 4. Change in Incremental Cost-effectiveness Ratio (ICER) with Varying Time on Prophylaxis 
5.3 Probabilistic Sensitivity Analysis 
In addition to varying all parameters in the model through one-way sensitivity analyses, a 
probabilistic sensitivity analysis can be performed. In a probabilistic analysis, all variables are 
varied simultaneously, and different values are selected from each parameter’s distribution for 
each of the 1,000 runs of the model that are performed, generating acceptability curves. An 
acceptability curve indicates how often a specific strategy is favored at specific willingness-to-pay 
(WTP) thresholds. A WTP threshold is a cost-per-QALY threshold – below the threshold, the cost-
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per-QALY is considered acceptable; above the WTP threshold, the cost-per-QALY is no longer 
deemed to be acceptable.  
 The acceptability curves for the probabilistic analysis of the model can be seen in Figure 
5. When a WTP threshold of $150,000/QALY or higher is chosen, the two-year prophylactic 
duration is favored. At a $200,000/QALY WTP threshold, two years of prophylaxis is favored in 
61.9% of model iterations. This means that, for 61.9% of the model’s 1,000 runs with values 
randomly selected from each variable’s distribution, two years of prophylaxis was the preferred 
strategy based on the ICER. 
 
 
Figure 5. Probabilistic Analysis Results Showing the Favored Strategy Across a Range of Costs per QALY 
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6.0  Analysis 
The ICER results, both in terms of life-years gained and QALYs, fall under the upper 
threshold of $200,000, indicate that extending prophylaxis duration to at least two years is 
economically reasonable. Sensitivity analyses confirm that extending even beyond that two-year 
duration may continue to be economically reasonable, dependent upon which cost-effectiveness 
threshold is selected. These results account for the possibility of increased resistant strain 
emergence that could accompany increased prophylaxis duration, and the toxicity of treatment for 
these resistant CMV strains. The favorability of increased prophylaxis duration confirms previous 
center-specific studies that found benefit in extending prophylaxis. Findings of this simulation 
model are strengthened by the use of national data, rather than data from a single center.  
The model does have some limitations. In using national data to estimate mortality 
following lung transplantation, these estimates do not distinguish between deaths attributable to 
CMV and deaths from other causes, including other opportunistic infections triggered by 
uncontrollable CMV infections. Thus mortality risk estimates of patients without CMV could be 
over-estimated, as continued prophylaxis would likely decrease mortality for CMV mismatch 
patients. This would, in turn, lower the ICER and result in a more cost-effective result. 
Furthermore, rejection episodes are thought to be associated with CMV in some way, though it is 
not yet known if the relationship is causal, or merely an association. In this model, however, 
rejection is treated as an independent event. 
 The use of national data to estimate utility values, used in the calculation of QALYs, 
presents another limitation. The utility values used the calculate the QALYs, and the resulting 
ICER, are relatively low. Utilities range from 0 (dead) to 1 (perfect health); utilities in this model 
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range from 0.25 – 0.70. Using published literature estimates, there is no differentiation between 
utility values of sensitive and resistant strains of CMV, though it is likely that they are different. 
When these utilities were varied over plausible ranges during sensitivity analyses, the results were 
not substantially changed, indicating that even with more accurate utility values, two years of 
prophylaxis remained the preferred strategy. 
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7.0  Discussion 
CMV viremia and disease are one of the most common infections following lung 
transplant, and CMV mismatch patients are at an increased risk for developing CMV [6-8]. The 
optimal prophylaxis duration with valganciclovir following transplantation, especially for 
mismatch patients, remains unknown, and different centers have varying protocols ranging from 
six months to over a year. Limited, site-specific studies have indicated that prophylaxis for longer 
than a year may be beneficial, but this contention has not yet been studied on a large scale [7]. 
Generally, along with extended periods of prophylaxis come concerns about increased risk of 
resistant CMV strains and about Foscarnet toxicity effects while treating those resistant strains.  
Understanding the correct duration of prophylaxis is important because of the association 
between CMV, BOS, episodes of acute rejection, and graft failure. Though the link is not fully 
understood yet, some association between CMV and episodes of acute rejection, potentially 
leading to graft failure, is noted [8, 11]. CMV is also associated with BOS, a progressive condition 
that limits survival following lung transplantation [7, 9, 11]. If prophylaxis is successful in 
decreasing or delaying CMV infection and disease, it would follow that BOS and graft failure 
could also be decreased or delayed.  
Model results do indicate that extending prophylaxis duration to two years does provide 
added benefit in the form of life-years gained and QALYs, and that extending even past those two 
years continue to provide extra benefit, even when taking into account the increased risk of 
resistance and associated toxicity of treatment. Further research could be performed to assess if 
increasing prophylactic duration does, in turn, decrease or delay the appearance of BOS and graft 
failure, both of which play major roles in post-transplant mortality. 
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 One important point of discussion, when considering these results, is the use of QALYs as 
a measure of effectiveness. Currently, QALYs are the most frequently used measure of 
effectiveness for cost-effectiveness studies, but they are not without controversy. The largest 
concern with QALYs is that they are not seen to be “patient-centric” [30, 31]. This means that they 
do not necessarily account for an individual patient’s wishes or preferences. Perhaps a patient has 
a major life milestone of a family member (wedding, graduation) that is very important to them, 
and that they want to make sure they’re present at – QALYs do not take this into account. It’s also 
possible that a patient does not place much value on losing a particular aspect of their health – for 
example, they do not mind being in pain, they are willing to lose some mobility – and QALYs are 
not able to account for this. Additionally, QALYs are based on a mathematical calculation, so the 
value of two years at “perfect health” (utility = 1) and four years at a lesser health (utility = 0.5) 
come out to the same QALY value, but may not be valued equally by the patient. These issues 
continue to be present when considering the instruments and tools used to elicit the utility values 
used in the QALY calculation. The individual methods referenced earlier (standard gamble, time 
trade-off, visual analog scale) are time intensive and individualized, and therefore not used 
frequently in favor of the use of standardized questionnaires. These questionnaires, however, do 
not account for individualized difference between patients [30]. There is also the larger issue on 
placing a value on a patient’s life or health, and making decisions based upon the various 
thresholds mentioned above [30]. When using a cost-effectiveness analysis to guide decision 
making, these factors need to be considered. 
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8.0  Conclusions, Recommendations, and Public Health Implications 
Based on the results of the model, extending prophylaxis duration to two years for CMV 
mismatch patients provides extra benefit, both in terms of life-years gained and QALYs, and is 
economically feasible. Both the base-case results and the subsequent sensitivity analyses support 
this conclusion. Given the lack of a single recommended strategy for prophylaxis for this particular 
group of patients, these results should be useful for lung transplant centers reviewing their 
prophylaxis strategy.  
This recommendation is especially important given the limited life expectancy following 
lung transplantation when compared to other solid organ transplants. Given the potential impact 
the increasing prophylactic duration to two years, or longer, has on the decrease on appearance of 
BOS and episodes of acute and chronic rejection, it is even more important that lung transplant 
centers consider these findings and begin implementing an extended prophylaxis regimen.  
 The public health implications, too, are clearly evident. Given that there are a limited 
number of organs available for transplantation, and that the demand outweighs the supply and is 
only continuing to grow, it follows that implementing the proper duration of prophylaxis will allow 
these organs to be used to their maximal benefit. The potential to decrease mortality of transplanted 
patients is pivotal, and the potential for reducing graft failure could also decrease or delay the need 
for re-transplants, again ensuring that donated organs are used to the greatest benefit on the 
population level. Increasing prophylaxis duration will improve outcomes overall. 
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